



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

5915 02 JAN 30 12:31

JAN 26 2004

Mr. Robert W. Pollock  
Vice President  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, New York 11590

Re: Docket No. 2003P-0284/CP1

Dear Mr. Pollock:

This letter confirms the substance of our January 22, 2004 telephone conversation. As we discussed, Forest Laboratories has told the Food and Drug Administration that it is marketing Lexapro 5 mg tablets. As a result, you agreed on behalf of Lachman Consulting Services, Inc., to withdraw the above referenced citizen petition. As we agreed, a copy of this letter has been filed in the docket with the instruction that this letter constitutes your formal withdrawal. Thank you.

Sincerely yours,

Aileen H. Ciampa  
Office of Regulatory Policy (HFD-7)  
Center for Drug Evaluation and Research

cc: HFA-305 (Docket No. 2003P-0284/CP1)

2003P-0284

LET 2